Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects

Sponsor

AstraZeneca (Industry)

Overall Status

Completed

CT.gov ID

NCT01365000

Collaborator

(none)

Enrollment

Location

Arms

Duration (Months)

10.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The is an assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects.

Condition or Disease	Intervention/Treatment	Phase
Healthy	Drug: NKTR118 Formulation 1 Drug: NKTR118 Formulation 2 Drug: NKTR118 Formulation 3 Drug: NKTR118 Formulation 1a Drug: NKTR118 Formulation 3a	Phase 1

Study Design

Study Type:

Interventional

Actual Enrollment :

21 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

None (Open Label)

Primary Purpose:

Basic Science

Official Title:

A Phase I, Open-label, Randomized, Balanced, Single-dose, Two-Part Study to Assess the Relative Bioavailability of NKTR-118 in Three Formulations Under Fasted (3-Way Crossover) and Fed (2-Way Crossover) Conditions in Male and Non-fertile Female Subjects

Study Start Date :

Jun 1, 2011

Actual Primary Completion Date :

Aug 1, 2011

Actual Study Completion Date :

Aug 1, 2011

Arms and Interventions

Arm	Intervention/Treatment
Experimental: NKTR118 Formulation 1 Fasted	Drug: NKTR118 Formulation 1 Oral dose, 25 mg
Experimental: NKTR118 Formulation 2 Fasted	Drug: NKTR118 Formulation 2 Oral dose, 25 mg
Experimental: NKTR118 Formulation 3 Fasted	Drug: NKTR118 Formulation 3 Oral dose, 25 mg
Experimental: NKTR118 Formulation 1a Fed	Drug: NKTR118 Formulation 1a Oral dose, 25 mg
Experimental: NKTR118 Formulation 3a FED	Drug: NKTR118 Formulation 3a Oral dose, 25 mg

Outcome Measures

Primary Outcome Measures

Pharmacokinetics after a dose of NKTR-118 25 mg by assessment of (Cmax) [day-1 to day 3]
Pharmacokinetics after a dose of NKTR-118 25 mg by assessment of time to Cmax (tmax) [day-1 to day 3]
Pharmacokinetics after a dose of NKTR-118 25 mg by assessment of half-life (t1/2λz) [day-1 to day 3]
Pharmacokinetics after a dose of NKTR-118 25 mg by assessment of area under concentration-time curve (AUC(0-t)) [day-1 to day 3]
Pharmacokinetics after a dose of NKTR-118 25 mg by assessment of area from time zero (pre-dose) extrapolated to infinity (AUC). [day-1 to day 3]

Secondary Outcome Measures

Safety and tolerability of NKTR-118 following administration of a single oral doses of NKTR-118 of 3 different formulations during fed and fasted conditions by assessing adverse events [Duration day -1 (Visit 2) to follow up (Visit 12)]
Safety and tolerability of NKTR-118 following administration of a single oral doses of NKTR-118 of 3 different formulations during fed and fasted conditions by assessing Safety Laboratory values [Duration day -1 (Visit 2) to follow up (Visit 12)]
Safety and tolerability of NKTR-118 following administration of a single oral doses of NKTR-118 of 3 different formulations during fed and fasted conditions by assessing 12-Lead Electrocardiograms [Duration day -1 (Visit 2) to follow up (Visit 12)]
Safety and tolerability of NKTR-118 following administration of a single oral doses of NKTR-118 of 3 different formulations during fed and fasted conditions by assessing Columbia-Suicide Severity Rating Scale (C-SSRS) [Duration day -1 (Visit 2) to follow up (Visit 12)]
Concentration of NKTR-118 in plasma samples after drug intake during Fed condition [Duration: Day 1 to day 4 at the 2 last inhouse stays]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 55 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Provision of signed and dated, written informed consent prior to any study-specific procedures
Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating, and must be of non-childbearing potential, confirmed at screening by fulfilling one of the following criteria:
Post-menopausal defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and with follicle stimulating hormone (FSH) levels in the laboratory defined post-menopausal range
Irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not tubal ligation
Volunteers must have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg
Volunteers must be able to understand and be willing to comply with study procedures, restrictions and requirements
Healthy male and non-fertile female volunteers ages 18 to 55 years inclusive, with suitable veins for cannulation or repeated venipuncture

Exclusion Criteria:

Any clinically significant disease or disorder (eg, cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the Investigator, may either put the healthy volunteer at risk because of participation in the study, or influence the absorption, distribution, metabolism, and excretion of drugs
Current smokers, those who have smoked or used nicotine products within the previous 3 months from the date of screening (Visit 1)
Plasma donation within 1 month of screening or any blood donation/blood loss >500 mL during the 3 months prior to screening or intention to donate blood or blood products during the study or within 3 months after the completion of the study
Positive screen for drugs of abuse, or cotinine (nicotine level above 400 ng/mL), at screening or admission and/or positive alcohol test at admission
Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of investigational product